PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
Quinola Mothergrain is a plant protein company that aims to disrupt the £3bn rice industry. It offers products that are aimed at boosting the economy and community development to a sustainably beneficial future. The company has received FDA approval in the US, and it has been listed in Ocado and Holland & Barret. It has won many awards including Best Organic Toddler Range (Loved by Parents Awards). The company will use the funds for improving revenues.
days to go:
Expired
investment:
£330,795
freemarketFX is an FCA authorised, innovative peer-to-peer currency exchange, focused on the high-value B2B commercial spot FX market.
days to go:
Expired
investment:
£645,496
Crosspay is a company that aims to make remittance simpler and cheaper. The company built its proprietary system in 2017 to bolster international transfers at a fraction of the money charged by traditional Over-The-Counter (OTC) services. It has since powered over 50,000 transactions across 50 countries with a cumulative value of approx £32,350,000. The company aspires to become the segment leader in the more than $200 billion global remittance market. Crosspay was rated 'Excellent' on Trustpilot. It also created white-labelled apps for charities and churches to host content, broadcast live and receive donations simultaneously, irrespective of location. The company has been invited to partner on an Innovate UK project. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£212,581
Reset Paris offers a wide range of high-end wellness services including spas, massage, sports and therapy classes. These services are delivered by highly qualified and experienced professionals with a holistic approach. Workshops based on matters like stress-relief, nutrition, focus, memory and sleep are also provided right at the office. The company has recruited a team of freelance professionals and tested their performance with B2B and B2C customers, developed a CRM platform and started collective classes with exceptional feedback. Reset is well-positioned to grow by selling health weeks to companies and increase its visibility through digital marketing.
days to go:
Expired
investment:
£111,430
OpenPlay is a marketplace for sports facilities and activities. It makes it easier for the public to find and book local venues and activities. It has a social layer on top to connect people to each other around their sporting interests and abilities. It makes money via a mixture of a subscription (SAAS) and commission based model for the use of its online bookings and customer management tools. We already have 80,000+ monthly visitors, 100,000+ bookings and over 2,000 venues listed.
days to go:
Expired
investment:
£75,000
